Bruno Paiva, PhD from the University of Navarra, Pamplona, Spain outlines his presentation on the role of minimal residual disease (MRD) in multiple myeloma, specifically its role as a prognostic factor and in the future as biomarker to aid in treatment decisions. Dr Paiva, outlines the importance of studying the biology of tumor resistant clones at the MRD level. The first reason discussed is to understand the mechanisms of ultra-chemoresistance in order to develop novel targets and therapy combinations. The second is to understand the biology and genetic features of the MRD cell. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
The importance of MRD in multiple myeloma patients
